LPA and cardiovascular disorder: Thus, LA in HD patients potentially may additionally reduce cardiovascular risk, and our report provides a first hint that Lp(a)‐Apheresis is applicable in hemodialysis patients with extremely high Lp(a) levels and progressive cardiovascular disease.